Menu
Innovation Observatory > Reports > Drugs > Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma – Adjuvant Therapy

< Back

Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma – Adjuvant Therapy

Drugs

Cancer and Palliative Care

December 2017


Paclitaxel formulated as albumin bound nanoparticles (Nab-paclitaxel) in combination with gemcitabine is being developed as a treatment option for patients with pancreatic cancer who have undergone surgery to increase the chances of being cured (‘adjuvant therapy’). Both drugs are chemotherapies already being used to treat metastatic pancreatic cancer and other types of cancers and are administered by injection.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Paclitaxel-nab (Abraxane) in combination with Gemcitabine for Resected Pancreatic Cancer - Adjuvant Therapy



Load More Related Posts
Get Alerts